Literature DB >> 17461858

Susceptibility to opportunistic infections in HIV-infected patients with increased CD4 T-cell counts on antiretroviral therapy may be predicted by markers of dysfunctional effector memory CD4 T cells and B cells.

Ma French1, Nm Keane, Ej McKinnon, S Phung, P Price.   

Abstract

OBJECTIVES: HIV-infected patients responding to combination antiretroviral therapy (ART) after experiencing severe immunodeficiency may exhibit persistent immune defects and occasionally experience opportunistic infections (OIs) despite increased CD4 T-cell counts. The investigation of immune defects in such patients was examined in this study.
METHODS: CD4 effector memory T-cell (T(em)-cell) function [assessed by blood cytomegalovirus (CMV) interferon-gamma (IFN-gamma) enzyme-linked immunosorbent spot-forming cell assay (ELISPOT) counts] and B-cell dysregulation [assessed by serum immunoglobulin A (IgA) and IgE levels] were examined in 27 patients with increased CD4 T-cell counts after receiving ART for over 2 years. Two of these patients and one other had developed OIs on ART and are described in detail.
RESULTS: Serum levels of IgA and IgE were higher than reference intervals (P<0.001) and CMV IFN-gamma ELISPOT counts were lower than those in non-HIV-infected controls (P<0.001) in the HIV-infected patients. Low CMV IFN-gamma ELISPOT counts were associated with high IgA levels (r=-0.5, P=0.01, Spearman's correlation test) and segregated with high IgE levels (P=0.06, Fisher's test). CMV IFN-gamma ELISPOT counts and serum IgA and IgE levels did not change significantly over a median time of 35 (range 8-60) months after the first measurement, whereas CD4 T-cell counts increased. All three patients who experienced OIs had repeatedly low CMV IFN-gamma ELISPOT counts and increased serum levels of IgA and/or IgE.
CONCLUSION: Low CD4 T(em)-cell function and B-cell dysregulation are immune defects that may persist independently of changes in the CD4 T-cell count in HIV-1-infected patients responding to ART and are associated with an increased risk of developing an OI.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17461858     DOI: 10.1111/j.1468-1293.2007.00445.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  7 in total

1.  Enhanced FCGR2A and FCGR3A signaling by HIV viremic controller IgG.

Authors:  Raymond A Alvarez; Ana M Maestre; Kenneth Law; Natasha D Durham; Maria Ines Barria; Akiko Ishii-Watabe; Minoru Tada; Manav Kapoor; Mathew T Hotta; Gabriela Rodriguez-Caprio; Daniel S Fierer; Ana Fernandez-Sesma; Viviana Simon; Benjamin K Chen
Journal:  JCI Insight       Date:  2017-02-23

2.  Direct phenotypical and functional dysregulation of primary human B cells by human immunodeficiency virus (HIV) type 1 in vitro.

Authors:  Ana Judith Perisé-Barrios; María Ángeles Muñoz-Fernandez; Marjorie Pion
Journal:  PLoS One       Date:  2012-07-02       Impact factor: 3.240

3.  Incomplete recovery of pneumococcal CD4 T cell immunity after initiation of antiretroviral therapy in HIV-infected malawian adults.

Authors:  Enoch Sepako; Sarah J Glennie; Kondwani C Jambo; David Mzinza; Oluwadamilola H Iwajomo; Dominic Banda; Joep J van Oosterhout; Neil A Williams; Stephen B Gordon; Robert S Heyderman
Journal:  PLoS One       Date:  2014-06-24       Impact factor: 3.240

Review 4.  Microbiota and Probiotics in Health and HIV Infection.

Authors:  Chiara D'Angelo; Marcella Reale; Erica Costantini
Journal:  Nutrients       Date:  2017-06-16       Impact factor: 5.717

5.  HIV-1 targets L-selectin for adhesion and induces its shedding for viral release.

Authors:  Joseph Kononchik; Joanna Ireland; Zhongcheng Zou; Jason Segura; Genevieve Holzapfel; Ashley Chastain; Ruipeng Wang; Matthew Spencer; Biao He; Nicole Stutzman; Daiji Kano; James Arthos; Elizabeth Fischer; Tae-Wook Chun; Susan Moir; Peter Sun
Journal:  Nat Commun       Date:  2018-07-19       Impact factor: 14.919

6.  Human protein Staufen-2 promotes HIV-1 proliferation by positively regulating RNA export activity of viral protein Rev.

Authors:  Atoshi Banerjee; Ronald Benjamin; Kannan Balakrishnan; Payel Ghosh; Sharmistha Banerjee
Journal:  Retrovirology       Date:  2014-02-13       Impact factor: 4.602

7.  The Effectiveness of a Pharmaceutical Care Model on Adherence to Antiretroviral Therapy: A SAME-Based Cohort Study in Brazil.

Authors:  Marli Gerenutti; Adriana Michel Vieira Martinez; Cristiane de Cassia Bergamaschi
Journal:  Adv Pharm Bull       Date:  2017-09-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.